at the 2014 Forum include:
Actinium Pharmaceuticals, Inc.
Argos Therpeutics, Inc
Avax Technologies, Inc
Biovest International, Inc.
NuvOx Pharma, LLC
OncoSec Medical, Inc.
Prolong Pharmaceuticals, LLC
Therapure Biopharma Inc.
Emerging Presenting Companies 2014 include:
Adherex Technologies, Inc.
Fusion Pharma, LLC
Intensity Therapeutics, Inc.
Inthera Bioscience AG
Neonc Technologies, Inc.
Providus Therapeutcis, Inc.
Sopherion Therapeutics, LLC
The 2nd Annual Sachs Cancer Bio Partnering & Investment Forum is designed to bring together thought leaders from cancer research institutes, patient advocacy groups, pharma and biotech to facilitate partnering and funding/investment. We expect around 200 delegates and there is an online meeting system and meeting facilities to make the event transactional. There will also be a track of about 30 presentations by listed and private biotechnology companies seeking licensing/investment.
The 2nd Annual Sachs Cancer Bio Partnering & Investment Forum
will cover the following topics in the program:
- Advances in Translational Research
- Strategies for Small Molecule and Biologicals Drug Development
- Deal Making
- Public & Private Partnerships
- Immunotherapies and Cancer Vaccines
- Case Study
Confirmed Speakers & Chairs include:
Anne Altmeyer, VP, Oncology Business Development & Licensing,
Novartis Pharmaceuticals Corporation
Beth Jacobs, Managing Partner, Excellentia Global Partners
Boris Peaker, Executive Director, Biotechnology Equity Research, Oppenheimer & Co. Inc.
Brian A. Sherer, Group Leader, Medicinal Chemistry, EMD Serono
Carole Nuechterlein, Head Roche Venture Fund, F.Hoffmann-La Roche Ltd. - Roche Venture Fund
Cornelia Reininger, CMO, Navida Biopharmaceuticals
Daryl Mitteldorf, Executive Director, Global Prostate Cancer Alliance
David Vera, Professor of Radiology and Co-Director,
UCSD In Vivo Cancer and Molecular Imaging Center
Dennis J. Purcell, Senior Managing Partner, Aisling Capital LLC
Doug Plessinger, Vice President of Clinical and Medical Affairs, Argos Therapeutics, Inc.
Dov Hass, Associate, Morgan, Lewis & Bockius LLP
Elizabeth Bachert, Sr. Director, Pfizer Inc.
Florian Schodel, Owner, Philimmune LLC
Francisco Civantos, Co-Director, Division of Head and Neck Surgery,
University of Miami Health System
Guillaume Vignon, Director Business Development Oncology – Global Business Development and Licensing, EMD Serono
Harry Glorikan, Managing Director, Strategy, Scientia Advisors,
a Precision for Medicine Company
James Mulé, Associate Center Director, Moffit Cancer Center
Kareem Reda, Associate Director, Business Development, Celgene
Keith Knutson, Program Director/Full Member/Principal Investigator, Cancer Vaccines and Immunotherapy Program, Vaccine and Gene Therapy Institute of Florida
Kristina Khodova, Head of Oncology Projects, Biomed Cluster, Skolkovo Foundation
Louis J. DeGennaro, Interim Prsident and CEO/Chief Mission Officer,
The Leukemia and Lymphoma Society
Louise M. Perkins, Chief Science Officer, Melanoma Research Alliance
Mara Goldstein, Managing Director & Senior Biotechnology Analyst, Cantor Fitzgerald
Martin Buckland, CBO Astex Pharmaceuticals and SVP, Corporate Development,
Otsuka Pharmaceutical Development & Commercialization, Inc.
Michael Goldberg, Managing Partner, Montaur Capital
Dr Michael J. Donovan, Vice Chair of Pathology, The Mount Sinai Research Venter
Nathan Tinker, Executive Director, NewYorkBIO
Nicholas Dracopoli, Vice President, Head, Biomarkers and Chief Scientific Officer, Next Generation Circulating Tumor Cell Technology, Janssen Research & Development LLC
Peter Hoang, Managing Director, Office of Innovations, Technology Based Ventures, The University of Texas MD Anderson Cancer Center
Philip Gotwals, Executive Director, Oncology Research Collaborations, Novartis Institutes for BioMedical Research, Inc.
Rick Guidotti, Founder and CEO, Positive Exposure
Robert Petit, Chief Scientific Officer, Advaxis
Stephen Brozak, Managing Partner and President, WBB Securities, LLC
Steven Young, President & COO, Addario Lung Cancer Medical Institute
Stuart Barich, Managing Director, Oppenheimer & Co. Inc.
Thomas H. Tulip, President and Chief Business Officer, Navidea Biopharmaceuticals
Tim Herpin, Vice President, Head of Transactions (UK), Business Development, AstraZeneca
Vikas Sharma, Director, Business Development, Rexahn Pharmaceuticals
Walter M. Capone, President, Multiple Myeloma Research Foundation
View the full list of 2013 Forum Speakers & Chairs >>
Presenting Opportunities for Biotech, Pharmaceutical companies and Patient Advocacy Groups
Presenting at the forum offers excellent opportunities to showcase activities and highlight investment and partnership opportunities. Biotech companies will be able to communicate investment and licensing opportunities. These are for both public and private companies. The audience is comprised of financial and industry investors. These are streamed 15 minute presentations. The patient advocacy presentations are 30 minutes.
Sachs forums are recognised as the leading international stage for those interested in investing in the biotech and life science industry and are highly transactional. They draw together an exciting cross-section of early-stage/pre-IPO, late-stage and public companies with leading investors, analysts, money managers and pharmas. The Boston forum provides the additional interaction with the academic/scientific and patient advocacy communities.
Sponsorship and Exhibition
Sachs Associates has developed an extensive knowledge
of the key individuals operating within the European and global biotech
industry. This together with a growing reputation for excellence puts
Sachs Associates at the forefront of the industry and provides a powerful
tool by which to increase the position of your company in this market.
Raise your company’s profile directly with
your potential clients. All of our sponsorship packages are tailor made
to each client, allowing your organisation to gain the most out of attending
our industry driven events.
To learn more about
Mina Orda +
44 (0)203 463 4890 or
by email: Mina Orda.
Click the cover below to download the full conference guide.
|To learn more about
contact Mina Orda
44 (0)203 463 4890 or
by email: Mina Orda.
|For special rates for conference accommodation contact Melanie Lozano at firstname.lastname@example.org or call 646-826-8627 and she will be happy to assist you with your booking.
| Pharma Licensing
the Forum include:
| Financial Advisory/
the Forum include:
| A.M.Pappas & Associates/Pappas Ventures
Advent Capital Management
Advent Healthcare Ventures
AE Smith Associates
Altius Strategy Consulting
Apache Capital Management
Eachwin Capital LP
Excellentia Global Partners
F. Hoffmann-La Roche AG Roche Venture Fund
GC Capital Partners
Hercules Technology Growth Capital,
J&J Innovation Center-Boston
Jefferies & Co, Inc.
Jina Ventures Inc.
Knoll Capital Management
Ladenburg Thalmann & Co Inc
Landmark Angels, Inc.
MedImmune Ventures Inc.
MedPro Investors LLC
Mehta Partners LLC
Mitchell and Sullivan Capital
MLV & Co.
MRL Ventures, Merck & Co.,Inc.
Oppenheimer & Co. Inc.
Oxford Finance LLC
Polar Star Ventures
Rockport Venture Partners
Silicon Valley Bank
Sphera Global Healthcare Fund
Steven Katz & Asscoiates, Inc.
Styvesant Capital Management Corp.
The Channel Group
Third Rock Ventures
Transnational Capital Corp
WBB Securities, LLC
Weiss Multi-Strategy Advisers
World Tech Ventures, LLC
Yorkville Advisors, LLC
| Meeting Scheduler